|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Short term (median follow-up of 16 months) clinical course data were consistent with nm23 RNA levels, in that 2 of 11 low nm23 RNA content patients (including one from the 0 involved lymph node group) developed metastases, while none of the high nm23 RNA patients have experienced recurrent disease.
|
2475243 |
1989 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development.
|
2509941 |
1989 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, in the colon, tissue-specific events dissociate nm23 expression from loss of tumor metastatic competence.
|
2023273 |
1991 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Reduced RNA and/or protein levels corresponding to the murine nm23-1 and human nm23-H1 complementary DNA clones have been correlated with high tumor metastatic potential in several rodent model systems and human breast carcinomas.
|
1988104 |
1991 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings indicate that, in contrast to a proposed role for nm23-H1 as a tumor metastasis suppressor, increased p19/nm23 protein in neuroblastoma is correlated with features of the disease that are associated with aggressive tumors.
|
2056128 |
1991 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Tests with probe YNZ 22.1, near p53, showed no significant association with distant metastases. nm23-H1 may be, or may be located near, a late-acting suppressor gene in colorectal carcinoma, in which deletions may have prognostic value.
|
1679868 |
1991 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It was found that patients developing metastases during the first 2 years after diagnosis had significantly lower levels of tumor nm23 expression (56% of the mean value) compared to patients with less aggressive disease (164%) (P < 0.0004).
|
1356624 |
1992 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The biological relevance of the novel phosphorylation identified herein is suggested by the direct correlation of in vivo Nm23 acid-stable phosphorylation levels, but not Nm23 NDPK activity, with suppression of tumor metastatic potential among control and nm23-1 transfected murine melanoma cells.
|
8245015 |
1993 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Reduced expression of nm23 RNAs/proteins has been associated previously with high tumor metastatic potential.
|
8384356 |
1993 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The product of Nm23 gene has been proposed as a candidate tumour metastasis suppressor protein.
|
8394105 |
1993 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The comparison of the staining intensity of the nm23-H1/NDP kinase in primary lesions of tumors with lymph node metastases and those without metastases revealed no statistically significant difference.
|
8396479 |
1993 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The data establish that nm23-H1 has functional suppressive effects on the tumor metastatic potential of a human breast carcinoma cell line, and suggest that it may regulate signal responsiveness in the colonization response.
|
8395676 |
1993 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic alterations either as a deletion in the coding sequence of nm23-H1 or as an allelic deletion were detected in four among eight colorectal adenocarcinomas associated with metastases in lymph nodes, lung, or liver.
|
7916650 |
1993 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis.
|
8392752 |
1993 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
In sharp contrast, the low frequency of loss at NME1 and its equal distribution in nodal metastasis-positive and -negative patients suggests that inactivation of this gene by allelic loss probably does not play a role in the development of regional metastases from these tumors.
|
8174043 |
1994 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Within histologic groups, we found no correlation between nm23 expression and nodal involvement of distant metastases.
|
8273382 |
1994 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
It was proposed that nm23 may function as a suppressor gene for tumour metastasis.
|
7931824 |
1994 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, the authors observed an inverse relationship between nm23-H1 expression and intrahepatic metastases of hepatocellular carcinomas.
|
8168032 |
1994 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nm23-H1 gene expression is inversely correlated with tumor metastatic potential in certain tumors, including melanomas, breast carcinomas, and hepatocellular carcinomas.
|
8270257 |
1994 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We further analysed the metastases with respect to allelic deletions at the chromosomal locus of nm23.
|
7981087 |
1994 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Nm23 is a gene associated with low tumor metastatic potential and has been proposed to be a metastasis suppressor gene.
|
8199988 |
1994 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The level of nm23 expression was highly heterogeneous in MM metastases, with a mean value which was higher than the mean level in normal tissues and naevi.
|
7981081 |
1994 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
High level of Nm23-H1 gene expression is associated with local colorectal cancer progression not with metastases.
|
7947079 |
1994 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, mRNA levels of both nm23 genes were not associated with histological grade, pathological stage, tumor metastasis or prognosis.
|
7614395 |
1994 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This overexpression was lost, however, in some advanced cases: 89% and 81% of TNM (tumour, node, metastases) stages 0-II showed Nm23-H1 and -H2 overexpression, respectively, which significantly differed from 47% and 38% of stage III-IV tumours.
|
8549951 |
1995 |